作为高强度他类药物治疗的辅助剂,欧比塞特拉皮布加以西西米布:一个随机的第二阶段试验
Christie M Ballantyne1, Marc Ditmarsch2, John Jp Kastelein3
1Department of Medicine, Baylor College of Medicine, Houston, Texas, United States.
Journal of clinical lipidology
|June 5, 2023
概括
在接受他类药物治疗的患者中,Obicetrapib与ezetimibe结合显著降低了LDL-C. 这种组合疗法在治疗失脂血症方面表现出良好的安全性和耐受性.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 失脂症的管理通常需要组合治疗来实现脂质目标.
- 像obicetrapib这样的胆固醇转移蛋白 (CETP) 抑制剂为脂质修饰提供了一种新的方法.
- 高强度他类药物治疗是降低心血管风险的基石.
研究的目的:
- 评估obicetrapib和ezetimibe联合治疗的安全性和降脂功效.
- 评估该组合作为高强度他类药物治疗的辅助剂,用于患有失脂血症的患者.
主要方法:
- 进行了一项为期12周的双盲随机二期试验.
- 参与者接受了高强度的他类药物治疗加上obicetrapib/ezetimibe组合,obicetrapib单一治疗或安慰剂.
- 关键的终点包括脂质度,阿波利波蛋白,脂质蛋白颗粒和安全性评估.
主要成果:
- 与安慰剂相比,组合治疗导致LDL-C降低63.4% (p<0.0001).
- 在使用组合治疗的患者中,100%的患者达到LDL-C<100 mg/dL.
- 通过活性治疗观察到非HDL-C和阿波利波蛋白B的显著降低.
结论:
- 奥比塞特拉皮布加以泽蒂米布的联合治疗是安全的,并且耐受良好.
- 这种组合有效地降低了在治疗他类药物时LDL-C升高的患者中的异构脂和脂蛋白参数.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
716
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
716
01:20Antiepileptic Drugs: Potassium Channel Activators
219
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
219
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
223
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
223
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
205
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
205
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
213
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
213
01:26Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15